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Abstract 
Patients with unstable angina, refractory to intensive medical therapy, are at high risk for developing thrombotic 
complications, uch as recurrent ischemia, myocardial infarction and coronary occlusion during coronary angio- 
plasty. As both platelet aggregation and/or thrombus formation play an important role in this ongoing ischemic 
process, a monoclonal platelet GPIIb/IIIa receptor antibody (c7E3) or thrombolytic therapy (alteplase) might be 
able to modify the clinical course and underlying coronary lesion morphology. To evaluate whether alteplase or 
c7E3 could influence the incidence of complications, we randomized 36 and 60 patients, respectively toalteplase 
or placebo, or c7E3 or placebo. All patients exhibited ynamic ECG changes and recurrent pain attacks, despite 
maximal tolerated medical therapy. Patients were randomized in both studies after initial angiography had demon- 
strated aculprit lesion amenable for angioplasty. After study drug infusion quantitative angiography was repeated 
and angioplasty performed. Recurrent ischemia during study drug infusion occured in 5, 6, 9 and 16 patients from 
the alteplase, placebo, c7E3 and placebo group, respectively. Major events defined as death, myocardial infarction 
or urgent intervention occurred in 7, 3, 1 and 7 patients, respectively. Two patients died: one in the alteplase group 
and one in the placebo group from the c7E3 study. The first patient due to retroperitoneal hemorrhage, the second 
as a result of recurrent infarction. Qualitative angiography showed resolution of clots in the c7E3 group only, while 
the same group of patients howed in 20% an improvement i  TIMI flow grade, without deterioration in any patient 
from this group. Quantitative angiography showed a significant improvement in percentage diameter stenosis in 
the c7E3 group, which was not observed in all three other groups, although differences between groups were 
not significant. Alteplase infusion in patients with refractory unstable angina did not change the clinical course, 
nor the coronary morphology, c7E3 on the other hand, both improved the clinical course and the coronary lesion 
morphology and rheology in the same category of patients. 
Introduction 
In 1989 Braunwald provided a classification for 
patients with unstable angina, based on the clinical cir- 
cumstances under which the syndrome occurred and 
the severity of the symptoms [1]. A further subdivi- 
sion took the intensity of medical treatment and the 
presence or absence of reversible lectrocardiographic 
changes during anginal attacks into consideration. 
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The underlying cause of unstable angina is thought 
to be rupture and ulceration of a pre existent atheroscle- 
rotic plaque, leading to platelet adhesion and aggrega- 
tion and thrombus formation [2, 3]. In most patients 
the syndrome can be stabilized with bed rest and anti- 
ischaemic and anti-thrombotic herapy [4]. 
However, in a minority of patients i chemic symp- 
toms continue in spite of intensive medical therapy. 
Such patients with unstable angina refractory to med- 
ical treatment are usually referred for urgent angio- 
plasty or bypass operation, which interventions are 
associated with a higher complication rate compared 
with stable or stabilized unstable angina patients [5, 6]. 
Prevention and or resolution of platelet aggregates and 
thrombi may help to prevent ongoing ischemic attacks 
and angioplasty complications. 
The value of administration f thrombolytic ther- 
apy in recent myocardial infarction has clearly been 
demonstrated. It opens occluded coronary arteries, 
improves left ventricular function and reduces mortali- 
ty by limiting infarct size [7, 8]. As unstable angina nd 
myocardial infarction share a common pathogenetic 
substrate, it seems reasonable that thrombolytic thera- 
py should ameliorate he syndrome of unstable angina 
pectoris [9]. Several studies have shown that throm- 
bolytic therapy can reduce the incidence of sudden 
death, the number of ischemic episodes, and improve 
the threshold for ischemia during atrial pacing [10-18] 
in patients with unstable angina. More recent random- 
ized trials found an angiographic mprovement after 
thrombolytic therapy in patients with unstable angina 
by openirlg occluded coronary arteries and reducing the 
incidence of intracoronary thrombi, however without 
decreasing inhospital cardiac events [19, 20]. 
CentoRx R (c7E3) is a monoclonal antibody that 
blocks the platelet fibrinogen receptor, glycoprotein 
IIb/IIIa. By preventing the binding of fibrinogen to 
the platelet surface, platelet aggregation and platelet 
thrombus formation are inhibited [21]. 
We designed two studies in patients with ongoing 
unstable angina despite medical treatment, who were 
candidates for coronary angioplasty. In the first study 
patients were randomized tothrombolytic therapy with 
alteplase or placebo. In the second study another group 
of patients with the same syndrome was randomized 
to CentoRx R (c7E3) or placebo, Quantitative analysis 
of coronary angiograms was essential in both studies, 
both before and after trial drug infusion. 
Pat ients  and  methods  
Patients election 
Included in both studies were patients between 21 and 
75 years and 
- manifesting recurrent episodes of chest pain after 
hospital admission, occurring at rest and pend- 
ing medical treatment, with at least one of these 
episodes with concomitant reversible ST-T seg- 
ment changes or persistent negative T-waves on 
the electrocardiogram; 
-undergoing a diagnostic coronary arteriogram 
within 24 hours (alteplase) or 12 hours (c7E3) of 
the most recent episode of coronary ischemia (chest 
pain and/or ST-T segment changes); 
-exhibiting a 'culprit' coronary lesion in a native 
vessel suitable for PTCA. A single vessel must be 
clearly indicated as ischemia related. Total occlu- 
sion of this vessel was considered acceptable for 
angioplasty, if it showed signs of recent occlusion 
such as the presence of intracoronary thrombi or 
contrast-staining at the obstruction site; 
-ability to perform a second coronary angiogram 
followed by angioplasty within 24 hours after an- 
domization; 
- providing informed consent after completion of the 
first diagnostic angiogram and prior to the initiation 
of protocol specific measures. 
Excluded for both studies were patients exhibiting fea- 
tures of ongoing ischemia which required immediate 
intervention, prior PTCA of the same coronary seg- 
ment within 6 months, recent major trauma includ- 
ing resuscitation, gastro intestinal or urinary tract 
bleeding within 3 months, persistent hypertension a d 
known bleeding disorders. The c7E3 trial also exclud- 
ed patients with prior Q-wave myocardial infarction 
within 7 days, and patients with a platelet count of less 
than 100,000/mm 3. 
Medical treatment 
Patients were designated as refractory unstable angina 
if anginal attacks continued espite bed rest and med- 
ical treatment which required minimally i.v. heparin 
and oral or i.v. nitroglycerin. After randomization all
patients were treated with the following combination 
of medication: 
-heparin 1,000 IU/hour, or a dose sufficient to pro- 
long the activated partial thromboplastin time to 
twice the control value, after a bolus injection of 
5,000 IU of heparin; 
- intravenous nitroglycerin ranging in dose from 50 
to 300/tg/min; 
-metoprolol 50-200 mg, in order to reduce heart 
rate to 60 beats/rain; 
- nifedipine in a dose of 40-120 rag/day. 
After informed consent and randomization by a tele- 
phone answering service, study drug infusion was start- 
ed as soon as possible, but at least within 4 hours after 
the first angiogram. 
For the alteplase trial a bolus injection of 10 mg 
i.v. was followed by an infusion of 50 mg in the first 
hour and 20 rag/hour for the subsequent 2 hours. Thus 
a total amount of 100 mg of alteplase or placebo was 
administered in 3 hours. 
For the c7E3 trial, patients received abolus dose of 
0.25 mg/kg followed by a 10 #g/rain continuous infu- 
sion for at least 18 hours. Patients to receive placebo 
were administered a bolus of human serum albumin, 
likewise followed by continuous infusion. The infusion 
continued until one hour following the completion of 
PTCA. 
Alteplase (Actilyse R) was supplied by Boehringer 
Ingelheim International, nd c7E3 (CentoRx R) by Cen- 
tocor, Malvern PA. 
Coronary arteriography and angioplasty 
Coronary arteriography and left ventricular angiog- 
raphy were performed as soon as possible after the 
qualifying anginal attack using the Judkins technique. 
Heparin 2,500 to 5,000 IU was administered at the 
beginning of the procedure. A second angiogram was 
performed within 24 hours after the start of study med- 
ication followed by angioplasty. The coronary artery 
responsible for the ischemia was identified by means 
of electrocardiographic location of the reversible ST-T 
segment changes, and left ventricular wall contrac- 
tion abnormalities. At least wo orthogonal projections 
were made of the culprit coronary artery, after injection 
of 1-3 mg of isosorbide dinitrate. During the first and 
the second angiogram the same projections and X-ray 
gantry setting were employed to compare lesion sever- 
ity. Low osmolar contrast medium (iopamidol) was 
used for all angiograms. All coronary and left ventric- 
ular angiograms were scored by at least two observers 
who were blinded with respect to the treatment assign- 
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ment. Qualitatively the following items were scored 
after the first contrast injection: 
-T1MI flow grade [22] of the culprit artery; 
-presence of intracoronary thrombus, defined as 
an intraluminal filling defect, visible during at 
least one complete cine-run, and surrounded on 
3 sides by contrast medium [23]. A total occluded 
coronary artery could contain a filling defect, but 
was not automatically scored as containing such a 
defect; 
- s tenos is  severity as visually assessed in multiple 
projections. 
Quantitative analysis of coronary angiograms 
Quantitative coronary angiography 
All cineangiograms were analyzed with the computer- 
assisted cardiovascular ngiography analysis system 
by the Core laboratory at Cardialysis, Rotterdam, NL. 
This system has been discussed in detail previously 
[24, 25]. The important steps will be briefly described. 
Any area sized 6.9 x 6.9 mm in a selected cineframe 
(overall dimensions 18 x 24 mm) encompassing the 
desired arterial segment can be digitized by a high- 
resolution CCD-camera with a resolution of 512 x 
512 pixels and 8 bits of gray level. Vessel contours are 
determined automatically based on the weighted sum 
of the first and second erivative functions applied to 
the digitized brightness information along scanlines 
perpendicular to the local centerline directions of an 
arterial segment. A computer-derived estimation of the 
original arterial dimension at the site of the obstruction 
is used to define the interpolated reference diameter. 
This technique is based on a computer-derived estima- 
tion of the original diameter values over the analyzed 
region (assuming there was no disease present) accord- 
ing to the diameter function. The absolute diameter of 
the stenosis as well as the reference diameter are mea- 
sured by the computer, which used the known guiding 
catheter diameter as a calibration factor. All contour 
positions of the catheter and arterial segments are cor- 
rected for pincushion distortion. 
'Plaque area' is the difference in area in mm 2 
between the reference and the detected contours over 
the length of the lesion [26]. 
The second angiogram to be followed by angio- 
plasty was performed between 12 and 24 hours in the 
alteplase trial and between 18 and 24 hours in the c7E3 
trial after the start of drug administration. Angiograms 
of the culprit artery were obtained in the same projec- 
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Table 1. Baseline clinical, electrocardiographic and angiographic characteristics of patient groups. 
Group Alteplase Placebo c7E3Fab Placebo 
N 19 17 30 30 
Male/Female 16/3 13/4 20/10 24/6 
Mean age (years) 59 62 61 60 
Previous infarct 7 10 9 16 
Previous CABG 0 1 0 2 
Previous PTCA 4 5 
Medication prior to qualifying ischemic attack 
Heparin 11 12 26 27 
Aspirin 5 5 21 23 
Nitrates 
* intravenous 9 9 24 27 
* oral 4 5 4 2 
/3-Blocker 16 9 22 24 
Calcium channel b ocker 7 t 1 15 22 
Ischemia related vessel 
Left anterior descending artery 11 6 16 14 
Left circumflex artery 2 4 8 6 
Right coronary artery 6 7 6 10 
Multivessel disease 5 5 6* 15" 
Ejection fraction 
< 0.50 3 2 n.a. n.a. 
> 0.50 16 14 
Unknown 0 1 
CABG = coronary artery bypass grafting; PTCA = percutaneous transluminal coronary angioplasty; 
n.a. = not assessed, * p = 0.03. 
tions as during the first angiogram, after intracoronary 
injection of isosorbide dinitrate. 
Assessments 
The efficacy of treatment was assessed in several ways: 
-Frequency of recurrent ischemic events between 
the first and the second angiogram (maximal 24 
hours). 
- Inc idence of major events, defined as death, 
myocardial infarction or urgent intervention dur- 
ing this observation period and during and after 
angioplasty. 
-Quantitat ive and qualitative analysis of all 
angiograms, before and after study drug infusion. 
Statistical analysis 
Differences between groups were analyzed with a two- 
tailed Student test. Changes in quantitatively mea- 
sured coronary artery severity stenosis in each group 
were compared with a two-tailed paired t test. Dif- 
ferences in incidence of recurrent ischemic attacks, 
myocardial infarction and presence of intracoronary 
clots were determined between treatment and respec- 
tive placebo groups with Fisher's exact test. 
Results 
Baseline characteristics 
The alteplase/placebo study was conducted between 
November 1987 and April 1989 in one hospital. 
The c7E3 Fab/placebo trial enrolled patients between 
September 1991 and July 1992 in five different hospi- 
tals. Baseline characteristics of the patients enrolled 
in both studies are summarized in Table 1. More 
patients in both placebo groups had sustained a pre- 
vious infarct compared with the treatment groups, but 
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left ventricular ejection fraction was similar in the 
alteplase/placebo groups, while this parameter was not 
assessed in the c7E3 Fab/placebo study. Also signif- 
icantly more patients in the placebo group from the 
last trial demonstrated multivessel disease, defined as 
a more than 50% diameter stenosis in one of the three 
main epicardial vessels. All other baseline parameters 
were similar between each treatment and respective 
placebo group. 
Recurrent ischemia 
Between the start of drug infusion and the second 
angiogram 5, 6, 9 and 16 patients from the alteplase, 
placebo, c7E3 Fab and placebo group respectively, had 
one or more episodes of recurrent ischemia defined 
as chest pain, with or without ECG changes. Severe 
recurrent ischemia, not subsiding with medical mea- 
sures, necessitated urgent coronary angioplasty in4, 1, 
0 and 3 patients from the alteplase, placebo, c7E3 Fab 
and placebo groups respectively. 
Major events 
In the two studies a major event defined as death, 
myocardial infarction or urgent intervention occurred 
in 7, 3, 1 and 7 patients from the alteplase, placebo, 
c7E3 Fab and placebo group respectively. The nature 
of these major events in all four groups is summarized 
in Table 2. 
Death in the alteplase patient occurred 48 hours 
after angioplasty, complicated by dissection of the right 
common iliac artery and retroperitoneal hemorrhage. 
One other patient from the placebo group in the 
c7E3 Fab study died, 26 days after allocation after 
a complicated clinical course, including two urgent 
PTCA procedures and myocardial infarction. 
Qualitative valuation of coronary angiograms 
Alteplase study c7E3Fab study 
Alteplase Placebo c7E3Fab Placebo - 
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Fig. 1. Qualitative coronary angiographic data of the ischemia 
related coronary artery before (B) and after (A) study drug infusion. 
O Totally occluded coronary artery 
@ lntracoronary filling defect 
O Patent coronary artery, without filling detect 
Note: The number of non totally occluded vessels, without filling 
defects in both angiograms, is depicted inthe bottom line. 
Table 2. Major events in all 4 study groups. 
Alteplase Placebo c7E3Fab Placebo 
N 19 17 30 30 
Death 1 0 0 1 
Myocardial infarction 7 3 1 4 
Before PTCA 4 1 0 1 
After PTCA 3 2 1 3 
Urgent procedure 5 1 7 
PTCA 4 1 3 
CABG 1 3 
Stent 1 
Total nr of patients 7 3 1 7 
with one or more 
major events 
CABG = coronary artery bypass grafting; 
PTCA = percutaneous transluminal coronary angioplasty. 
TIMI flow grade 3 in culprit arteries, assessed cen- 
trally by the Core Laboratory, was present in 57 to 
76% of all patients at the first angiogram. Of all 4 
groups studied, a substantial improvement in coronary 
blood flow occurred after treatment in the c7E3 Fab 
patient group only, while all three other groups howed 
both improvement and deterioration i TIMI flow score 
(Table 3). 
Extensive filling defects in the coronary arteries 
were seldom encountered. Most filling defects were 
single, visible in more than one direction and located 
distally from the culprit lesion. The number of intra- 
coronary clots, and total occlusions from both studies, 
in the pre and post treatment angiogram are shown in 
Fig. 1. In the alteplase study new occlusions of culprit 
arteries occurred in both groups, while other occlud- 
ed coronary arteries became patent after study drug 
infusion. In the c7E3 Fab study a new occlusion was 
observed in the placebo group only, but also restored 
patency of a total occluded vessel in two cases with 
thrombotic remnants in one case. Three out of five 
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Table 3. Qualitative angiographic data. 
Group Alteplase Placebo c7E3Fa Placebo 
N 19 17 30 30 
TIMI flow B A B A B A B A 
0 2 3 1 1 1 1 4 3 
1 0 0 0 0 2 1 0 1 
2 3 3 3 2 10 5 7 6 
3 14 13 13 14 17 23 19 20 
Improved 3 2 6 4 
Worsened 4 2 0 3 
In~acoronaryfilling defect 1 4 2 2 5 2 1 1 
B = before study drug infusion; A = after study drug infusion. 
Table 4. Quantitative angiographic data from the first angiogram (I) and after study drug infusion (II) and the difference between 
both measurements (II-I). 
Treatment Alteptase (n = 19) Placebo (n = 17) c7E3Fab (n = 30) Placebo (n = 30) 
Variable n n n n 
DS (%) 
I 19 66.7 (16.1) 17 63.1 (13.1) 30 65.7 (8.6) 29 67.7 (16.1) 
II 19 67,0 (14.8) 17 61.6 (13.5) 30 62.3 (10.5) 29 65.6 (15.8) 
II-I 19 0.3 (20.2) 17 - 1.6 (16,2) 30 - 3.4 (6.7)* 29 ' - 2.1 (12.4) 
MLD (mm) 
I 19 1.0 (0.4) 17 1.1 (0.5) 30 0.9 (0.3) 30 0.9 (0.4) 
II 19 0.9 (0.4) 17 1.1 (0.5) 30 1.0 (0.3) 30 0.9 (0.4) 
II-I 19 -0,1 (0.6) 17 0.0 (0.4) 30 0.1 (0.2) 30 0.0 (0.3) 
Ext Ob (mm) 
I 17 7.1 (2.2) 16 9,2 (4.0) 29 7.3 (2.2) 26 7.2 (3.4) 
II 17 7.0 (2.6) 16 7.8 (3.3) 29 6.9 (2.1) 26 7.3 (2,9) 
II-I 16 - 0.1 (1.4) 15 - 0.9 (2.0) 29 - 0.5 (1.2)* 26 0.3 (1.8) 
Plq Area (mm 2) 
I 17 10.0 (5.3) 16 12,0 (7.6) 29 8.2 (3.4) 29 9.1 (6.8) 
II 17 9.5 (6.8) 16 8.9 (5.3) 29 7.1 (2.5) 27 8.6 (4,8) 
II-I 15 -0.2 (3.0) 15 -2.1 (3.6)* 29 -1.1 (1.9)* 25 -0.5 (3.3) 
AS (%) 
I 14 87.7 (9.6) 15 84.6(15.7) 20 89.2 (6,7) 21 90.7 (7.9) 
II 16 88.2 (8.4) 14 85.5 (17.4) 23 88.3 (8.4) 22 89.6 (10.2) 
II-I 12 - 1.1 (10.4) 14 1.1 (9.6) 19 1.8 (8.1) 19 - 1.3 (6.4) 
DS = diameter stenosis; MLD = miminal lumen diameter; AS = area stenosis; Ext Ob = extent of the obstruction; 
Plq area = plaque area; * p [PI]DW 0,05. Data are given as mean values (standard eviation). 
coronary  c lo ts  reso lved  in the  t reatment  group  o f  the  
c7E3  study.  
Quantitative coronary angiographic analysis 
Quant i ta t ive  coronary  ang iograph ic  data  are summa-  
r i zed  in Tab le  4. One  pat ient  f rom the  c7E3  Fab  s tudy  
with a very proximal LAD lesion is missing in the 
calculated percentage diameter stenosis, because the 
reference diameter could not be ascertained. All video- 
densitometric area calculations of more than 100% 
obstruction were left out, while plaque area and extent 
of obstruction could naturally only be calculated in 
patent coronary arteries. 
In the alteplase study, no significant changes were 
observed in the quantitative parameters nor within nor 
between groups. 
In the c7E3 Fab study significant decreases in per- 
centage diameter stenosis, extent of obstruction and 
plaque area were observed in the c7E3 Fab patients. 
In the placebo group the same changes were 
observed to a lesser extent, except for the extent of 
obstruction, which decreased in the c7E3 Fab patients, 
but increased inthe placebo group patients. Differences 
between groups were not significant. 
Discussion 
When thrombolytic therapy revived for the treatment 
of acute myocardial infarction and showed beneficial 
effects, a logic next step was to add thrombolytics 
to the drug regimen of patients with ongoing unsta- 
ble angina refractory to that regimen. Several studies 
have been conducted since using different thrombolyt- 
ic agents in different classes of unstable angina [11- 
20, 27-31]. Only the study of Gold, including only 
23 patients, showed a beneficial reduction in cardiac 
events from 55% to 9%. And although inclusion cri- 
teria varied in the interval between the last anginal 
attack and study drug infusion, in the classification 
according to Braunwald, and the presence of angio- 
graphically demonstrated significant coronary artery 
disease, all shared a common outcome of no clinical 
benefit. Only the study of Ardessino [28] showed a 
lower mortality in the group treated with alteplase, all 
other studies manifesting an equal [19] or higher mor- 
tality in the group treated with a thrombolytic agent 
[13, 18-20, 30, 31]. Also the incidence of myocardial 
infarction during and after treatment with thrombolytic 
agents was higher in the treated patients than in those 
receiving placebo (29 of 270 and 15 of 289 patients 
respectively), while both groups were on intravenous 
heparin as background therapy [12, 13, 17-20, 29, 31, 
32]. 
Some studies included quantitative analysis of 
coronary angiograms before and after study drug infu- 
sion, the angiography result being part of the inclu- 
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sion process [12, 13, 17, 19, 20, 28, 31]. These 
studies all showed a minimal reduction in percentage 
diameter stenosis, both in the treatment and place- 
bo groups, reaching only statistical significance in the 
treated group in two studies [17, 20]. Part of the prob- 
lem of most studies was the small number of patients 
included, varying from 24 to 159 patients. The two 
studies with a significant reduction in diameter steno- 
sis in the treated groups included a relatively large 
number of patients of 70 and 159 respectively. 
The thrombolytic study reported here treating 
patients with refractory unstable angina showed ahigh 
incidence of cardiac events in both groups, possi- 
bly reflecting the severe nature of the syndrome in 
these patients, already treated with routine medication, 
including heparin and aspirin. 
Two recent editorials addressed the relative ineffi- 
cacy of thrombolytic agents in patients with unstable 
angina [9, 33]. They both explain the apparent dis- 
crepancy between the effects of thrombolytic agents 
in myocardial infarction and unstable angina pectoris 
by the difference in underlying disease and enhanced 
thrombosis formation. Opening of an occluded artery 
as in myocardial infarction, and keeping an artery open 
as in unstable angina require different approaches~ In 
the Unasem study e.g. a significant reduction in diam- 
eter stenosis was only achieved by opening occlud- 
ed arteries with anisoylated plasminogen streptokinase 
activator complex [20]. Several studies suggest hat 
thrombolytic therapy might enhance thrombin forma- 
tion and activate platelets to further coronary thrombo- 
sis [34-40]. These effects of tissue plasminogen acti- 
vator can be countered by the monoclonal antiplatelet 
GPIIb/IIIa receptor antibody as has been demonstrated 
in a canine model [41]. 
It is conceivable that this antibody alone prevents 
occlusion of coronary arteries in unstable angina and 
prevents platelet aggregation. In fact we demonstrat- 
ed that c7E3 Fab ameliorated the clinical course of 
patients with refractory unstable angina. Also the mod- 
est but significant reduction in diameter stenosis of the 
culprit lesion corroborates these optimistic expecta- 
tions. 
These results look quite promising and might 
be confirmed in a larger trial which is now under- 
way. Quantitative assessment ofcoronary arteriograms 
could make the clinical results more understandable, 
all the more because the absence of clinical benefit 
in patients with unstable angina pectoris treated with 
thrombolytic agents has not been attended by quanti- 
tative improvement of coronary artery lesions. 
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